PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
150.00
+0.30 (+0.20%)
At close: 2:24PM IDT
Stock chart is not supported by your current browser
Previous Close149.70
Open148.00
Bid150.00 x 128000
Ask150.90 x 209400
Day's Range148.00 - 151.20
52 Week Range108.00 - 276.70
Volume25,825
Avg. Volume210,024
Market Cap223.794M
Beta (3Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswirelast month

    Protalix BioTherapeutics Reports 2018 Full Year Results and Provides Corporate Update

    CARMIEL, Israel, March 18, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization.

  • GlobeNewswirelast month

    Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call

    CARMIEL, Israel, March 13, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire2 months ago

    Protalix BioTherapeutics to Hold Full-Year 2018 Financial Results and Corporate Update Conference Call on March 14, 2019

    CARMIEL, Israel, March 06, 2019 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • GlobeNewswire3 months ago

    Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

    CARMIEL, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) --  Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease is the subject of an oral presentation at the 15th Annual WORLDSymposiumTM 2019.  The conference is taking place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida, and the oral presentation is scheduled for Thursday, February 7, 2019 at 8:30 AM ET. PRX-102 is the Company’s plant cell-expressed recombinant, PEGylated, cross-linked α-galactosidase-A drug candidate for the treatment of Fabry disease.  The BRIGHT study is a 12-month, open-label switchover study to assess the safety, efficacy and pharmacokinetics of pegunigalsidase alfa 2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT): Fabrazyme® or Replagal®.  As of December 23, 2018, 28 patients had been enrolled in the BRIGHT study, and 15 of those patients had completed 9 months of treatment.  Samples from these 15 patients underwent pharmacokinetic (PK) evaluation and were tested for the presence of anti-drug antibodies (ADA).

  • GlobeNewswire3 months ago

    Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium™ 2019

    CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary pharmacokinetic (PK) data from its phase III BRIGHT study of pegunigalsidase alfa for the treatment of Fabry disease at the 15th Annual WORLDSymposium™ 2019.  The conference will take place February 4-8, 2019 at the Hyatt Regency Orlando, Orlando, Florida. Preliminary results of a Phase 3 study,” highlighting PK and safety data will be presented by Mr. Myrl D. Holida, PA, of the University of Iowa Health Care in Iowa City, Iowa, a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease, on Thursday, February 7, 2019 at 8:30 AM ET.

  • GlobeNewswire4 months ago

    Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease

    CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for the BALANCE and BRIGHT phase III clinical trials which, collectively with the BRIDGE study, comprise the phase III clinical development program for PRX-102 for the treatment of Fabry disease.  The BRIGHT study is approximately 90% enrolled and the BALANCE study is approximately 70% enrolled.

  • Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 months ago

    Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Protalix: 3Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...

  • GlobeNewswire6 months ago

    Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.

  • Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
    Zacks6 months ago

    Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know

    Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks9 months ago

    Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates

    Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
    Simply Wall St.9 months ago

    Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?

    In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...

  • Associated Press9 months ago

    Protalix: 2Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...

  • Benzinga9 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...